Evaluating nipocalimab for adults with chronic inflammatory demyelinating polyneuropathy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to assess the safety and efficacy of nipocalimab in delaying relapse in adults diagnosed with chronic inflammatory demyelinating polyneuropathy (CIDP). Participants who initially respond to nipocalimab will be compared to those receiving a placebo. The study includes adults aged 18 and older with specific disability scores related to their condition. The trial is structured in two phases, focusing on both the effectiveness and safety of the treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults greater than or equal to (\>=) 18 years of age at the time of consent and as applicable, must also meet the legal age of consent in the jurisdiction in which the study is taking place
* Diagnosed with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) according to criteria of the European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) 2021, progressing or relapsing forms. CIDP diagnosis to be adjudicated by independent committee during screening period
* Inflammatory Neuropathy Cause and Treatment (INCAT) disability score between 2 and 9 at the Run-In Baseline visit for participants entering Run-In, or Stage A Baseline visit for participants directly entering Stage A. Participants with an INCAT score of 2 at trial entry must have this score exclusively from the leg disability score
* Fulfilling any of the following treatment conditions: a) Currently treated with oral corticosteroids (CS) less than or equal to (\<=) 20 milligrams (mg)/day; or b) Currently treated with pulsed CS, and/or intravenous immunoglobulin (IVIg) or subcutaneous immunoglobulin (SCIg) and the participant is willing to discontinue no later than the run-in baseline visit; or c) Currently treated with oral CS greater than (\>) 20 mg/day and the participant is willing to taper to \<=20 mg/day during the run-in period; or d) Without previous treatment (treatment naive); or treatment with CS and/or IVIg or SCIg discontinued at least 3 months prior to screening (untreated)
* Active disease as determined by CIDP Disease Activity Status (CDAS) score \>= 3
* Other protocol-defined inclusion criteria will apply

Exclusion Criteria:

* Has a history of severe and/or uncontrolled hepatic (example, viral/alcoholic/autoimmune hepatitis/cirrhosis and/or metabolic liver disease), gastrointestinal, renal, pulmonary, cardiovascular, psychiatric, neurological or musculoskeletal disorder, hypertension and/or any other medical or uncontrolled autoimmune disorder(s) (example, diabetes mellitus) or clinically significant abnormalities in screening laboratory that, might interfere with the participants full participation in the study, or might jeopardize the safety of the participant or the validity of the study results
* Pure sensory CIDP or chronic immune sensory polyradiculopathy (CISP) (EAN/PNS definition)
* Any other disease that could better explain the participant's signs and symptoms, such as significant persisting neurological deficits from stroke or central nervous system (CNS) trauma or peripheral neuropathy from another cause such as connective tissue disease or systemic lupus erythematosus
* Polyneuropathy of other causes, including the following: Multifocal motor neuropathy (MMN); Monoclonal gammopathy of uncertain significance with antimyelin associated glycoprotein (anti-MAG) immunoglobulin M (IgM) antibodies; Hereditary motor neuropathy; Hereditary neuropathy with liability to pressure palsies (HNPP); Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin change syndromes; Lumbosacral radiculoplexus neuropathy; Polyneuropathy most likely due to diabetes mellitus; Polyneuropathy most likely due to systemic illnesses; Drug- or toxin-induced polyneuropathy Note: A concomitant polyneuropathy of other causes (example, a mild, stable diabetic polyneuropathy) is not necessarily exclusionary if chronic inflammatory demyelinating polyneuropathy (CIDP) is confirmed as the main diagnosis, as determined by the investigator and confirmed by the adjudication committee
* Has known allergies, hypersensitivity, or intolerance to nipocalimab or its excipients
* Other protocol-defined exclusion criteria will apply

Where it's running

• Instituto Fleni
  Buenos Aires, Argentina Recruiting
• INECO Neurociencias Orono
  Rosario, Argentina Recruiting
• The Ottawa Hospital Ottawa NeuroMuscular Centre
  Ottawa, Canada Recruiting
• Attikon General Hospital of Athens
  Athens, Greece Recruiting
• Ahepa Hospital Aristotle University of Thessaloniki
  Thessaloniki, Greece Recruiting
• Clinical Research Institute S.C.
  Tlalnepantla, Mexico Recruiting

+70 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Study Contact
• Email: Participate-In-This-Study1@its.jnj.com
• Phone: 844-434-4210

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Nipocalimab in breast milk after a single IV dose in healthy lactating women

  This study tests how much nipocalimab shows up in breast milk after a single IV dose in healthy breastfeeding women.

  Recruiting Phase 1 Janssen Research & Development, LLC · Salt Lake City, Utah · NCT07669077

• Nipocalimab for adults with moderate to severe systemic lupus erythematosus

  This trial tests nipocalimab versus placebo in adults with moderate to severe lupus to see if it reduces disease activity and symptoms.

  Recruiting at 270 sites Phase 3 Janssen Research & Development, LLC · Beverly Hills, California and 271 other locations · NCT07438496

• Nipocalimab versus efgartigimod for generalized myasthenia gravis

  This trial will test whether nipocalimab or efgartigimod works better to reduce muscle weakness in adults with AChR-positive generalized myasthenia gravis who have meaningful symptoms despite stable therapy.

  Recruiting at 30 sites Phase 3 Janssen Research & Development, LLC · Fullerton, California and 30 other locations · NCT07217587

• Evaluating nipocalimab and IVIG for preventing fetal and neonatal thrombocytopenia

  This study is testing if a new treatment called nipocalimab can help pregnant women with a history of fetal and neonatal thrombocytopenia keep their babies' platelet levels safe compared to standard treatment with IVIG.

  Recruiting at 37 sites Phase 3 Janssen Research & Development, LLC · Birmingham, Alabama and 37 other locations · NCT06533098

• Evaluating nipocalimab for preventing fetal and neonatal alloimmune thrombocytopenia

  This study is testing whether nipocalimab can help pregnant women with a history of a blood condition called fetal and neonatal alloimmune thrombocytopenia prevent serious problems for their babies.

  Recruiting at 6 sites Phase 3 Janssen Research & Development, LLC · Leuven and 20 other locations · NCT06449651

• Nipocalimab treatment for pregnant women at risk of severe fetal anemia

  This study is testing if nipocalimab can help pregnant women at risk of having babies with severe anemia due to a past condition, to see if it improves the health of their newborns.

  Recruiting at 66 sites Phase 3 Janssen Research & Development, LLC · La Jolla, California and 68 other locations · NCT05912517

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.